Navigation Links
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
Date:6/9/2009

-Second Data Set Presented at MDS-

PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future.

The NT-201 data presented at the Movement Disorder Society's annual meeting includes the following three abstracts: Efficacy and safety of NT-201 (Xeomin(R); botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients, Efficacy and safety of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in treatment-naive cervical dystonia patients, and Repeated injections of NT-201 (Xeomin; botulinum neurotoxin type A free from complexing proteins) in upper limb spasticity patients.

Eric Pappert, M.D., Vice President of Medical Affairs, Merz Pharmaceuticals, USA said, "These findings suggest Xeomin, the brand name for NT-201 in Europe, may be a new option in the treatment of movement disorders in the United States."

First Study -Title

Efficacy and safety of NT-201 (Xeomin(R), botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients authored by Susanne Grafe, Cynthia Comella, Joseph Jankovic, Daniel Truong, and Angelika Hanschman.

Method

CD patients previously treated with another brand of BoNTA were randomized to placebo, 120 U NT 201, or 240 U NT-201. Following injection, patients were evaluated at 4 weeks using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Adverse events (AEs) were also collected up
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
2. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
3. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
4. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
5. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
6. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
11. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... NEW YORK, Jan. 26, 2012 Walgreens, the nation,s largest ... research toward curing, treating, and preventing type 1 diabetes (T1D) ... raise more than $1.4 million in 2011 for JDRF causes. ... JDRF to raise funds for research to put an end ...
... Varian Medical Systems (NYSE: VAR ) today announced ... Therapy Centre LLC to equip a new proton therapy facility ... Varian will equip the new center with a ProBeam™ system ... linear accelerators. Equipment delivery and installation is expected to commence ...
Cached Medicine Technology:Walgreens Raises More Than $1.4 Million in 2011 Campaign to Support Type 1 Diabetes Research 2Walgreens Raises More Than $1.4 Million in 2011 Campaign to Support Type 1 Diabetes Research 3Varian Medical Systems Books $77 Million Order to Equip Proton Treatment Center in Saudi Arabia 2
(Date:4/18/2014)... group of scientists from the University of Kentucky ... Aging has found interesting new information in a ... disease (PD). , Published in the journal ... cognitive function in depressed and non-depressed patients with ... used to treat motor symptoms of Parkinson,s disease ...
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... Calif. (April 18, 2014) ― A new study in ... weekly patterns in health-related Google searches reveals a recurring ... strategies. , Investigators from San Diego State ... the Monday Campaigns, analyzed "healthy" Google searches (searches that ... "healthy diet") originating in the U.S. from 2005 to ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... woman who gave birth to octuplets after fertility treatment ... fear they may end up in a similar situation. ... is the California case unusual, but there are strict ... IVF treatments are safe, and that the risks of ...
... non-judgmental, emphatic listeners to callers looking to talk, vent or just share ... ... -- The stock market is in the tank … the economy is ... are common phrases that many people today are expressing, but words not ...
... WOODLANDS, Texas, March 17 eCardio Diagnostics ( ... launched an Academic Medicine initiative to provide a ... is the first time an arrhythmia monitoring company ... responsibilities of academic medical centers. "At eCardio, ...
... Inc. (Nasdaq: DIET ), a leading provider of ... results for the fourth quarter and twelve months ended December ... million, compared to $6.9 million in the prior year period. ... share, for the fourth quarter of 2008 compared to $(4.2) ...
... 16 The leader of the nation,s largest veterans ... a meeting with President Obama today to discuss a ... the treatment of military veterans who have suffered service-connected ... plan to require private insurance carriers to reimburse the ...
... Spread on Web Sites, YouTubeDon,t Move From ,Democracy ... Services to Danger in Rescinding Conscience ProtectionsWASHINGTON, March ... in the United States to tell the Obama ... governing conscience protections for health care workers.This is ...
Cached Medicine News:Health News:Washington DC-area IVF Specialist Suheil Muasher, MD Addresses Fears of Infertility Treatments after Octuplet Mom News 2Health News:Washington DC-area IVF Specialist Suheil Muasher, MD Addresses Fears of Infertility Treatments after Octuplet Mom News 3Health News:Washington DC-area IVF Specialist Suheil Muasher, MD Addresses Fears of Infertility Treatments after Octuplet Mom News 4Health News:Confidential Listening Service We Just Listen Launches, Providing Americans a Private Platform to Express Their Thoughts and Feelings 2Health News:eCardio Diagnostics Launches Academic Medicine Initiative 2Health News:eDiets.com(R) Announces Q4 2008 Results 2Health News:eDiets.com(R) Announces Q4 2008 Results 3Health News:eDiets.com(R) Announces Q4 2008 Results 4Health News:eDiets.com(R) Announces Q4 2008 Results 5Health News:eDiets.com(R) Announces Q4 2008 Results 6Health News:eDiets.com(R) Announces Q4 2008 Results 7Health News:The American Legion Strongly Opposed to President's Plan to Charge Wounded Heroes for Treatment 2Health News:The American Legion Strongly Opposed to President's Plan to Charge Wounded Heroes for Treatment 3Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 3
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Erbium YAG Extended Ablation laser enables the ... peel with outstanding results and no downtime., The ... fluence level with an extra long pulse width ... Peeling is spread over 3-5 days, and occurs ...
... art software package designed to assist in the ... a lens manufacturer with years of experience in ... designed to help you run your lab the ... software dictates., ,Designed specifically for integrated retail and ...
The new Vascular ClearWay Irrigating PTFE Balloon Catheter is a revolutionary micro-porous PTFE balloon catheter designed for the removal of fresh, soft emboli and thrombi, and for intraluminal irrig...
Medicine Products: